Insider Trading Alert - INO, NAV And TRLA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, April 15, 2014, 62 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $15.81 to $34,205,434.59.

Highlighted Stocks Traded by Insiders:

Inovio Pharmaceuticals (INO) - FREE Research Report

Kim Jong Joseph who is Chief Executive Officer at Inovio Pharmaceuticals bought 25,000 shares at $2.25 on April 15, 2014. Following this transaction, the Chief Executive Officer owned 6.0 million shares meaning that the stake was reduced by 0.42% with the 25,000-share transaction.

The shares most recently traded at $2.45, up $0.20, or 8.16% since the insider transaction. Historical insider transactions for Inovio Pharmaceuticals go as follows:

  • 4-Week # shares bought: 190,000
  • 12-Week # shares bought: 190,000
  • 24-Week # shares bought: 190,000

The average volume for Inovio Pharmaceuticals has been 8.1 million shares per day over the past 30 days. Inovio Pharmaceuticals has a market cap of $641.2 million and is part of the health care sector and drugs industry. Shares are down 7.93% year-to-date as of the close of trading on Tuesday.

Inovio Pharmaceuticals, Inc., together with its subsidiaries, discovers, develops, and develops synthetic vaccines and immune therapies focusing on cancers and infectious diseases. Currently there are 4 analysts that rate Inovio Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on INO - FREE

TheStreet Quant Ratings rates Inovio Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share. Get the full Inovio Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Investors Need to Closely Watch Mario Draghi's Speech at Jackson Hole: Market Recon

Resist All the Dow 22K Hoopla: Cramer's 'Mad Money' Recap (Wednesday 8/2/17)

Chevron, Universal Display, Dynavax Technologies, Schlumberger: 'Mad Money' Lightning Round

These Stocks Are Ready to Reverse Course

Biotech Movers: Sarepta, Inovio, Mylan